Q3 (Q3 2026 Earnings Call Presentation FINAL)

Third Quarter 2026 Earnings Conference Call

11/5/2026

The release, accompanying slides, and replay webcast are available online at https://www.teleflex.com (click on Investors)

An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 5, 2026 either on the Teleflex website or by telephone.

The call can be accessed by dialing

1 833 309 1852 (U.S. and Canada) or 1 929 828

5978

(all other locations).

The confirmation code is 893 259 060.

President and CEO

Executive VP and CFO

VP, Investor Relations and Strategy Development

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; statements regarding our planned uses of the net proceeds from the closing of the sale of our OEM business (the "OEM Strategic Divestiture"), including, without limitation, with respect to the paydown of debt and the repurchase of shares of our outstanding common stock; statements regarding our expectations with respect to the timing for closing of the sales of our Acute Care and Interventional Urology businesses (which, together with the OEM Strategic Divestiture, we refer to as the "Strategic Divestitures"); statements regarding projected costs, savings and timing with respect to restructuring activities related to the Strategic Divestitures; our expectation that the transition services and manufacturing services agreements to be entered into in connection with the Strategic Divestitures will offset stranded costs on an annualized basis; statements regarding EZPLAZ; statements regarding our BIOMAG-II and BIOMAG-III trials and our BIOMAG-LL clinical study; our expectation that our financial profile will be meaningfully stronger starting in 2027; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation. You should not place undue reliance on these statements or the scientific data presented.

This presentation refers to certain non-GAAP financial measures, including, but not limited to, pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins, adjusted selling, general and administrative expenses, adjusted research and development expenses, adjusted income before taxes, adjusted income tax expense and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

This document contains certain highlights with respect to our third quarter 2026 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended September 30, 2026 located in the investor section of our website at https://www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the Securities and Exchange Commission.

Unless otherwise noted, the following slides reflect continuing operations.

Jason Weidman President and CEO

• Q3'26 pro forma adjusted constant currency revenue grew 3.0%

  year-over-year

• Q3'26 adjusted gross margin of 66.8% and adjusted operating margin of 25.0%

• Q3'26 adjusted EPS of $2.63, a 39.2% increase year-over-year

OEM Divestiture Update

• Closed the OEM Strategic Divestiture for $1.5 billion in proceeds ($1.25 billion after-tax)

• OEM Strategic Divestiture generates the majority of our expected

and

proceeds from the Strategic Divestitures - funded debt paydown

share repurchase

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

EZPLAZTM: Building a Long-Term Growth Driver

• First and only FDA-licensed freeze dried plasma; approved in late July; customer interest has been high

• Stored at room temperature and ready to reconstitute in minutes - makes plasma available on the battlefield, in air and road ambulances, and in trauma centers without waiting to thaw1,2

• Flexible bag is a meaningful differentiator vs. glass-container formats expected from future entrants; first-mover advantage positions EZPLAZ to set the standard

• Initial priority is the U.S. government and military, expected to account for the majority of current manufacturing capacity; Department of War discussions continue to progress

EXPECTED REVENUE PROFILE

1. Pusateri AE, Given MB, Schreiber MA, et al. Dried plasma: state of the science and recent developments. Transfusion. 2016;56 Suppl 2:S128-S139. doi:10.1111/ trf.13580

2. Hervig T, Doughty H, Ness P, et al. Prehospital use of plasma: the blood bankers' perspective. Shock. 2014;41 Suppl 1:39-43. doi:10.1097/SHK.0000000000000144

Rx Only

See appendices to this presentation for EZPLAZ™ Freeze Dried Plasma Indications and Important Safety Information.

FreesolveTM Resorbable Magnesium Scaffold (RMS) Breakthrough Device Designation Received

• Received FDA Breakthrough Device Designation (BDD) for FreesolveTM RMS in percutaneous coronary intervention (PCI), building on the 2024 BDD for below-the-knee (BTK) treatment of chronic limb-ischemia

• BIOMAGTM-II: enrollment completed ahead of schedule; one-year data vs. XIENCETM Drug-Eluting Stent (DES) expected in late 2027

• BIOMAGTM-III: U.S. pivotal trial underway to support a future Premarket Approval (PMA) submission

  BIOMAGTM-LL Clinical Study Enrollment Completed

• Completed enrollment of 102 patients across 14 European centers evaluating 35 mm and 40 mm FreesolveTM RMS lengths in de novo coronary lesions up to 38 mm

• Primary endpoint is 12-month target lesion failure (TLF)*

• Study will help determine whether longer scaffold lengths may enable treatment of long lesions with fewer implants, potentially simplifying procedures and reducing scaffold overlap

• 35 mm and 40 mm lengths are also included in the ongoing BIOMAGTM-III pivotal clinical trial

*Target lesion failure (TLF) is a composite clinical endpoint commonly used to assess the safety and effectiveness of coronary interventional devices.

CAUTION-Investigational device. Limited by the United States law to investigational use.

FreesolveTM RMS is not for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location.

Sales ($M) Commentary

$243.5

Reported rev. growth: 4.7% Pro forma adj. const. curr. rev. growth: 4.6%

• In Q3'26, growth was primarily driven by our intraosseous portfolio, hemostatic products, and peripheral access products

• As expected, saw some distributor inventory destocking associated with normalization following the lidocaine recall earlier in the year

  Interventional

$210.3

Reported rev. growth: (2.6)% Pro forma adj. const. curr. rev. growth: 0.2%

$114.0

Reported rev. growth: 4.2% Pro forma adj. const. curr. rev. growth: 5.1%

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. Pro forma adjusted constant currency revenue growth is as compared to the prior year period.

Three Months Ended September 30, 2026

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

1. Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments

2. Adjustments are inclusive of discontinued product adjustments

3. In 2025, amounts reflect the impact from decreases in our reserves related to the Italian payback measure pertaining to prior years.

   ‌Financial Overview

   John Deren

   Executive VP and CFO

   ‌Q3'26 Financial Review of Continuing Operations

   Adjusted GAAP

   2025 62.3%

   450

   bps

   2026 66.8%

   2025 32.7%

   2026 34.3%

   2025 7.6%

   2026 7.5%

   2025 22.0%

   300

   bps

   2026 25.0%

   2025 $1.89

   2026 $2.63

   2025 51.5%

   2026 65.0%

   2025 36.6%

   2026 38.9%

   2025 7.8%

   2026 7.6%

   Gross Margin

2025 (11.0)%

2026 18.6%

2025

2026

• The year-over-year adjusted earnings per share increase was driven by the following:

  -$1.32

$1.30

Note: See appendices for reconciliations of non-GAAP financial information.

Capital return commitment

• $1 billion share repurchase authorization and $800 million reduction in debt

• Near-term capital return to shareholders to be primarily funded by after-tax proceeds from the Strategic Divestitures

  Share repurchases

• From July 1, 2026 through the date of this presentation, the Company has repurchased $350 million of its common stock through an ASR program ($250 million) and open market purchases ($100 million)

• This consisted of 2.7 million shares repurchased at an average price of $128.96 per share

• As of November 5, 2026, the Company had $400 million remaining available under the current authorization

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 13

Revenue

• Maintaining 2026 pro forma adjusted constant currency revenue growth range of 3.5% to 4.5% year-over-year

• Reducing 2026 GAAP revenue from continuing operations growth range to 13.2% to 14.2% year-over-year due to changes in foreign currency exchange rates

  Earnings Per Share

  • Increasing 2026 Adjusted diluted EPS from continuing operations range to $7.50 to $7.75

  • Increasing 2026 GAAP EPS from continuing operations range to $2.84 to $3.09

  Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 14

  ‌2026 Guidance Considerations

  • 3.5% to 4.5% pro forma adjusted constant currency revenue growth for 2026

    Pro Forma Adj. CC Revenue Growth

• Excludes foreign exchange, Italian payback measure, and discontinued products

• Includes Vascular Intervention revenue for the first half of 2025

Adjusted Earnings Per Share

• 2026 adjusted EPS from continuing operations in the range of $7.50 to $7.75

• Assumes:

  • ~20.0% adjusted operating margin inclusive of IEEPA tariff refunds of $16.5M recognized in the third quarter 2026

  • ~11.5% adjusted tax rate

  • $85M of net interest expense

  • 42.5 million shares outstanding for 2026

  • Reflects execution of capital allocation strategy, including pay off of $700 million Term Loan A-2, pay down of a portion of the revolving credit facility, and $600 million of share repurchases

  • Excludes transition services (TS) and manufacturing services (MS) benefits from the Acute Care & Interventional Urology Strategic Divestiture

  • Excludes future repurchases under the $1B buyback program funded by Strategic Divestitures proceeds, of which $400 million is remaining

  • Excludes incremental debt paydown with net proceeds from the Strategic Divestitures

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 15

Adjusted Operating Margin

• TS/MS agreements expected to offset stranded costs on an annualized basis following close of AC/IU Strategic Divestiture

• Previously announced restructuring programs to result in ~$50 million of pre-tax savings on an annualized basis upon completion in mid-2028, which will contribute to mitigating stranded costs

  Debt Paydown

  • Intent to pay down ~$800M in debt (paid off $700 million of debt associated with the Vascular Intervention acquisition), with net proceeds from the Strategic Divestitures

  Share Repurchase

  • Remaining $400 million authorization under previously announced share repurchase program to be funded with net proceeds from the Strategic Divestitures

• Working on additional cost savings to further mitigate stranded costs

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 16

Note: See appendices for reconciliations of non-GAAP financial information.

Note: See appendices for reconciliations of non-GAAP financial information.

Strong Q3 Performance; Raising FY26 Adjusted EPS Guidance

• Expanded adj. margins; grew adj. EPS

• Vascular & Surgical solid; Interventional moving in the right direction

• Maintaining FY26 revenue growth outlook

Meaningful Progress on Our Transformation

• Interventional integration advancing with new leadership in place

• Confident in completing the AC/IU divestiture

• Advancing longer-term growth with EZPLAZ and Freesolve

Clear Path to a Meaningful Step-Up in 2027+

• Priorities: strengthen foundation, accelerate organizational effectiveness, elevate growth profile

• Planned completion of $1B buyback after AC/IU close

• 2027 step-up in adj. op. margin & EPS; sustainable growth beyond

19 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

‌Thank You!

20 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure:

Pro forma adjusted revenue. This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; (ii) exclude the items described in Italian payback measure; and (iii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.

Pro forma adjusted constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Note: Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future.

Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; (ix) other items; and (x) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impacts of (i) restructuring and optimization charges; (ii) acquisition, integration and divestiture related items; (iii) Italian payback measure; (iv) other items; and (v) intangible amortization expense.

Adjusted operating profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; and (ix) other items.

Adjusted selling, general and administrative expenses. This measure excludes, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) acquisition, integration and divestiture related items; (iii) Italian payback measure; (iv) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (v) intangible amortization expense; and (vi) other items.

Adjusted research and development expenses. This measure excludes the impact of certain costs associated with the registration of medical devices under the European Union Medical Device Regulation.

Adjusted income before taxes. This measure excludes, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; and (ix) other items.

Adjusted income tax expense. This measure excludes, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) Italian payback measure; (v) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vi) intangible amortization expense; (vii) tax adjustments; and (viii) other items.

Adjusted tax rate. This measure is the percentage of the Company's adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring and optimization charges;

(ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) Italian payback measure; (vi) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vii) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (viii) intangible amortization expense; and (ix) tax adjustments.

The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached:

Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These charges include qualified restructuring costs (which may include costs associated with employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related expenses (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.

Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.

Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance.

Other - These are discrete items that occur sporadically and can affect period-to-period comparisons. The benefit from IEEPA tariff refunds received in 2026 related to tariffs incurred in 2025 were excluded from the Company's non-GAAP financial measures for the third quarter of 2026 because it does not represent normal, recurring operating expenses, making it difficult to contribute to a meaningful evaluation of our period-over-period operating performance.

MDR - The European Union ("EU") has adopted the EU Medical Device Regulation ("MDR"), which replaces the existing Medical Devices Directive ("MDD") and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

Nine Months Ended September 30, 2026

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

1. Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments

2. Adjustments are inclusive of discontinued product adjustments

3. In 2025, amounts reflect the impact from decreases in our reserves related to the Italian payback measure pertaining to prior years.

   ‌Appendix A2 - Segment Revenue Review by Region

   	Three Months Ended		Nine Months Ended
   	September 30,	September 28,	September 30,	September 28,
   	2026	2025	2026	2025
   		Reported Revenue
   Vascular
   North America	$155.6	$151.9	$469.1	$444.2
   Rest of World	87.9	80.6	257.5	233.4
   Total	243.5	232.5	726.6	677.6
   Interventional
   North America	104.1	105.7	302.5	266.5
   Rest of World	106.2	110.2	324.3	163.5
   Total	210.3	215.9	626.8	430.0
   Surgical
   North America	64.8	63.9	191.1	179.6
   Rest of World	49.2	45.6	141.9	127.5
   Total	114.0	109.5	333.0	307.1
   Segment Net Revenues
   North America	324.5	321.5	962.7	890.3
   Rest of World	243.3	236.4	723.7	524.4
   Total	$567.8	$557.9	$1,686.4	$1,414.7

   ‌Appendix B1 - Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

   Three Months Ended September 30, 2026

   	Revenue	Gross margin	SG&A (1)	R&D (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
   GAAP Basis - Continuing Operations	$567.8	65.0%	38.9%	7.6%	18.6%	$83.1	$28.8	34.7%	$1.30

   Adjustments

   Restructuring and optimization charges (A) - 0.1 (0.5) - 0.5 3.7 0.7 0.09

Acquisition, integration and divestiture

related items (B)

- - (0.7) - 0.7 4.3 0.9 0.08

ERP implementation - - (0.6) - 0.6 3.3 0.5 0.07

Intangible amortization expense - 3.2 (2.8) - 6.0 33.9 4.5 0.70

Adjustments total - 1.8 (4.6) (0.1) 6.4 40.0 (15.1) 1.33

Adjusted basis $567.8 66.8% 34.3% 7.5% 25.0% $123.1 $13.7 11.1% $2.63

Notes:

See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

Nine Months Ended September 30, 2026

Adjustments

related items (B)

Notes:

1. Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenue.

2. Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenue.

   See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

   ‌Appendix B4 - Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

   	Revenue	Gross margin	SG&A (1)	R&D (1)	Operating margin (2)	Income before income taxes	Income tax expense	Effective income tax rate	Diluted earnings per share from continuing operations
   GAAP Basis - Continuing Operations	$1,423.7	57.1%	35.0%	6.7%	7.3%	$37.0	$(25.1)	(67.9)%	$1.38

   Adjustments
   Restructuring and optimization charges (A)	-	1.0	-	-	1.3	18.4	3.1		0.35
   Impairment charges	-	-	-	-	7.6	108.1	24.7		1.86
   Acquisition, integration and divestiture related items (B)	-	3.0	2.8	-	0.3	2.6	12.2		(0.21)
   Separation costs	-	-	-	-	0.2	2.6	0.1		0.06
   Italian payback measure	(9.0)	(0.2)	0.1	-	(0.6)	(8.9)	(0.9)		(0.18)
   ERP implementation	-	-	(0.9)	-	0.9	13.3	2.1		0.25
   MDR	-	-	-	(0.2)	0.2	2.9	0.1		0.06
   Intangible amortization expense	-	3.2	(2.7)	-	6.0	85.0	10.8		1.65
   Tax adjustments	-	-	-	-	-	-	7.1		(0.16)
   Adjustments total	(9.0)	7.0	(0.7)	(0.2)	15.9	224.0	59.3		3.68
   Adjusted basis	$1,414.7	64.1%	34.3%	6.5%	23.2%	$261.0	$34.2	13.1%	$5.06

   Nine Months Ended September 28, 2025

   Notes:

   1. Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenue.

‌Appendix B Tickmarks

1. Restructuring and optimization charges - For the three months ended September 30, 2026, a pre-tax restructuring benefit of $0.3 million was offset by restructuring related charges of $4.0 million. For the three months ended September 28, 2025, pre-tax restructuring charges were $1.6 million and restructuring related charges were $3.3 million. For the nine months ended September 30, 2026, pre-tax restructuring charges were $16.7 million and restructuring related charges were $25.9 million. For the nine months ended September 28, 2025, pre-tax restructuring charges were $4.3 million, restructuring related charges were $11.5 million, and product optimization charges were $2.6 million.

2. Acquisition, integration and divestiture related items - For the three and nine months ended September 30, 2026, these charges primarily related to the acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended September 30, 2026 these charges included acquisition and integration costs of $4.2 million. For the nine months ended September 30, 2026 these charges included acquisition and integration costs of $20.9 million and inventory step up costs of $8.0 million. For the three and nine months ended September 28, 2025, these charges primarily related to the acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the three months ended September 28, 2025 the charges included inventory step-up costs of $42.1 million and integration and acquisition costs of $4.4 million. For the nine months ended September 28, 2025 the charges included inventory step-up costs of $42.1 million and acquisition and integration costs of $26.5 million, which were offset by a benefit of $82.2 million related to non-designated foreign currency forward contracts.

3. Other - For the three months ended September 30, 2026, other items included a benefit from IEEPA tariff refunds of $8.8 million partially offset by legal and advisory fees incurred in response to an activist investor campaign of $0.1 million and a loss on extinguishment of debt of $3.4 million. For the nine months ended September 30, 2026, other items included a benefit from a litigation settlement of

$25.0 million and IEEPA tariff refunds of $8.8 million partially offset by legal and advisory fees incurred in response to an activist investor campaign of $3.7 million, a loss on extinguishment of debt of $4.5 million, and charges incurred in connection with the credit agreement refinancing of $1.0 million.

33 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

• Pro forma adjusted revenue increased 4.2% year-over-year on a constant currency basis

• Revenue increased 18.5% year-over-year on a GAAP basis

  Gross margin

• Adjusted gross margin of 63.3%, down 80 bps year-over-year

• GAAP gross margin of 59.8% vs. 57.1% in the prior year period

  Operating margin

• Adjusted operating margin of 20.9%, down 230 bps year-over-year

• GAAP operating margin of 11.8% vs. 7.3% in prior year period

  Effective tax rate

• Adjusted tax rate of 12.7% vs. 13.1% in prior year period

• GAAP tax rate of 26.7% vs. (67.9)% in prior year period

  Earnings per share

• Adjusted EPS of $5.73, up 13.2% year-over-year

• GAAP EPS of $2.11 vs. $1.38 in prior year period

Note: See appendices for reconciliations of non-GAAP financial information.

‌Rx Only

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EZPLAZ™ FREEZE DRIED PLASMA

INDICATIONS

EZPLAZ™ Freeze Dried Plasma (FDP) is indicated for transfusion in adults when plasma is required and other plasma products are not available. Indications include:

• Management of preoperative or bleeding patients who require replacement of multiple plasma coagulation factors [e.g., liver disease, disseminated intravascular coagulation (DIC)]

• Patients undergoing massive transfusion who have clinically significant coagulation deficiencies

• Patients taking warfarin who are bleeding or need to undergo an invasive procedure before vitamin K could reverse the warfarin effect or who need only transient reversal of warfarin effect IMPORTANT SAFETY INFORMATION

  CONTRAINDICATIONS

  Do not use EZPLAZ™ FDP:

• In patients with history of hypersensitivity to fresh frozen plasma (FFP), liquid plasma or to plasma-derived products including any plasma proteins

• In patients with IgA deficiency

WARNINGS AND PRECAUTIONS

As with other licensed blood products, EZPLAZ™ FDP may cause adverse events known to be associated with transfusion of blood products. For a complete list and further details not provided below, please refer to the Circular of Information.

Hemolytic Transfusion Reactions

Hemolytic transfusion reactions can occur with ABO blood group mismatches. EZPLAZ™ FDP is provided in blood group type AB or type A low titer Anti-B (< 1:200 by saline tube method).

Transfusion-Related Acute Lung Injury (TRALI)

To mitigate the risk of TRALI, EZPLAZ™ FDP is manufactured from FFP donated by male only donors.

Infection Risk from Human Plasma

Because EZPLAZ™ FDP is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, bacteria, and theoretically the variant Creutzfeldt-Jakob disease (vCJD) agent.

Hypersensitivity Reaction

Hypersensitivity reactions, including anaphylaxis, may occur. Discontinue the transfusion if signs or symptoms of hypersensitivity occur and treat appropriately.

Specific Therapies

EZPLAZ™ FDP may be less effective in correcting certain coagulopathies when therapies targeting specific coagulation factor deficiencies or anticoagulant effects are available. In such situations, clinicians should consider the use of targeted therapies, when clinically appropriate, including vitamin K for urgent vitamin K antagonist reversal, fibrinogen-containing products for hypofibrinogenemia, specific coagulation factor concentrates, or specific reversal agents for non-vitamin K antagonist anticoagulants. Selection of therapy should be based on the patient's clinical condition, urgency of correction, and availability of alternative treatments.

Volume Expansion

EZPLAZ™ FDP is not intended for routine volume expansion. When administered in the absence of a documented coagulation factor deficiency or plasma protein deficiency, the expected clinical benefit may be limited, and alternative volume expanders are generally more appropriate. Clinicians should consider alternative therapies based on the patient's clinical needs.

Elevated INR

Transfusion of EZPLAZ™ FDP may not result in meaningful correction of a minimally elevated international normalized ratio (INR), such as values between 1.5 and 1.7. In these situations, the likelihood of achieving clinically significant hemostatic benefit may be low, and alternative management strategies should be considered based on the patient's overall clinical condition.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Teleflex at 1-866-246-6990 and FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

For additional Safety Information, please see Full Prescribing Information at https://www.teleflex.com/EZPLAZPI.